Positron emission tomographic scans in lymphoma

Convention and controversy

Stephen M. Ansell, James Olen Armitage

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The use of sensitive and specific imaging techniques for accurate initial staging and evaluation of response to therapy in patients with lymphoma is essential for their optimal management. Fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) integrated with computed tomography (CT) has emerged as a powerful imaging tool and is being routinely used in staging, response evaluation, and posttreatment surveillance in patients with non-Hodgkin lymphoma and Hodgkin lymphoma. PET/CT is currently widely used in clinical practice, but the established clinical benefit is currently restricted to the posttreatment evaluation of Hodgkin lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. Although used in other histologic subtypes and in other clinical situations including response assessment, its impact on patient outcome remains to be demonstrated. We performed a literature search of PubMed from 1999 to 2011 using the following keywords: PET scan, FDG-PET, PET/CT, lymphoma. This review addresses the challenges and controversies in the use of PET/CT scans in the management of patients with lymphoma.

Original languageEnglish (US)
Pages (from-to)571-580
Number of pages10
JournalMayo Clinic Proceedings
Volume87
Issue number6
DOIs
StatePublished - Jan 1 2012

Fingerprint

Lymphoma
Positron-Emission Tomography
Electrons
Hodgkin Disease
Follicular Lymphoma
Lymphoma, Large B-Cell, Diffuse
Fluorodeoxyglucose F18
PubMed
Non-Hodgkin's Lymphoma
Tomography
Positron Emission Tomography Computed Tomography
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Positron emission tomographic scans in lymphoma : Convention and controversy. / Ansell, Stephen M.; Armitage, James Olen.

In: Mayo Clinic Proceedings, Vol. 87, No. 6, 01.01.2012, p. 571-580.

Research output: Contribution to journalArticle

@article{297308f29e384266b48cc1cd83f93dfc,
title = "Positron emission tomographic scans in lymphoma: Convention and controversy",
abstract = "The use of sensitive and specific imaging techniques for accurate initial staging and evaluation of response to therapy in patients with lymphoma is essential for their optimal management. Fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) integrated with computed tomography (CT) has emerged as a powerful imaging tool and is being routinely used in staging, response evaluation, and posttreatment surveillance in patients with non-Hodgkin lymphoma and Hodgkin lymphoma. PET/CT is currently widely used in clinical practice, but the established clinical benefit is currently restricted to the posttreatment evaluation of Hodgkin lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. Although used in other histologic subtypes and in other clinical situations including response assessment, its impact on patient outcome remains to be demonstrated. We performed a literature search of PubMed from 1999 to 2011 using the following keywords: PET scan, FDG-PET, PET/CT, lymphoma. This review addresses the challenges and controversies in the use of PET/CT scans in the management of patients with lymphoma.",
author = "Ansell, {Stephen M.} and Armitage, {James Olen}",
year = "2012",
month = "1",
day = "1",
doi = "10.1016/j.mayocp.2012.03.006",
language = "English (US)",
volume = "87",
pages = "571--580",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "6",

}

TY - JOUR

T1 - Positron emission tomographic scans in lymphoma

T2 - Convention and controversy

AU - Ansell, Stephen M.

AU - Armitage, James Olen

PY - 2012/1/1

Y1 - 2012/1/1

N2 - The use of sensitive and specific imaging techniques for accurate initial staging and evaluation of response to therapy in patients with lymphoma is essential for their optimal management. Fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) integrated with computed tomography (CT) has emerged as a powerful imaging tool and is being routinely used in staging, response evaluation, and posttreatment surveillance in patients with non-Hodgkin lymphoma and Hodgkin lymphoma. PET/CT is currently widely used in clinical practice, but the established clinical benefit is currently restricted to the posttreatment evaluation of Hodgkin lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. Although used in other histologic subtypes and in other clinical situations including response assessment, its impact on patient outcome remains to be demonstrated. We performed a literature search of PubMed from 1999 to 2011 using the following keywords: PET scan, FDG-PET, PET/CT, lymphoma. This review addresses the challenges and controversies in the use of PET/CT scans in the management of patients with lymphoma.

AB - The use of sensitive and specific imaging techniques for accurate initial staging and evaluation of response to therapy in patients with lymphoma is essential for their optimal management. Fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) integrated with computed tomography (CT) has emerged as a powerful imaging tool and is being routinely used in staging, response evaluation, and posttreatment surveillance in patients with non-Hodgkin lymphoma and Hodgkin lymphoma. PET/CT is currently widely used in clinical practice, but the established clinical benefit is currently restricted to the posttreatment evaluation of Hodgkin lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. Although used in other histologic subtypes and in other clinical situations including response assessment, its impact on patient outcome remains to be demonstrated. We performed a literature search of PubMed from 1999 to 2011 using the following keywords: PET scan, FDG-PET, PET/CT, lymphoma. This review addresses the challenges and controversies in the use of PET/CT scans in the management of patients with lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=84863457697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863457697&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2012.03.006

DO - 10.1016/j.mayocp.2012.03.006

M3 - Article

VL - 87

SP - 571

EP - 580

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 6

ER -